SUMMARY Six isolates of a strain (MRP-MT) of Trichomonas vaginalis obtained from a woman before and after unsuccessful treatment with metronidazole had an appreciably lower susceptibility to metronidazole both in vitro in the aerobic tube assay and in vivo in the mouse assay than did control strains from patients cured with standard doses of the drug.
Introduction
Resistance of Trichomonas vaginalis to 5-nitroimidazole drugs has been a matter of controversy.' Although drug resistance of trichomonads has not been shown convincingly in vitro there have been clinical reports of treatment failures. The possibility of the existence of metronidazole-resistant strains of T vaginalis has been met with considerable scepticism.2' Persistent trichomonal infections which could not be ascribed to reinfection were attributed to altered pharmacokinetics in patients5 or to a lowering of the drug concentration in the vagina by concomitant bacteria.4 6 7 Recently, however, a decreased susceptibility to metronidazole has been proved unequivocally in several strains of T vaginalis isolated from patients who were refractory to treatment. [8] [9] [10] Meingassner et all' showed the importance of assay conditions in the in-vitro detection of resistance of trichomonads to 5-nitroimidazoles. Using a laboratory-developed drug-resistant strain of the found that the resistance of this strain could be ascertained in vitro only under aerobic conditions. Aerobic assay systems have been developed to allow reliable determinations of trichomonad susceptibility to 5-nitroimidazoles in vitro.8 10 We report metronidazole resistance in a strain of T vaginalis isolated from a female patient who did not respond to several courses of treatment with 5-nitroimidazoles. 13 Patient and methods
CASE REPORT
The patient was a 41-year-old woman who gave a four-year history of recurrent vulvo-vaginitis caused by T vaginalis. During this period she had been treated unsuccessfully seven times with metronidazole (Entizole, Polfa) and once with tinidazole (Fasigyn, Pfizer). In five of the treatment courses metronidazole (250 mg) was taken orally twice daily supplemented with 500 mg inserted vaginally once daily for 10 days. In one course the daily dose of metronidazole was increased to 1 g, and in another five 250-mg oral tablets (a total of 1250 mg metronidazole) were taken daily for three days. 394
Tinidazole was given orally in 150 mg tablets twice daily for seven days.
When she was examined in our department the patient had an acute vulvo-vaginitis with an inflammatory discharge containing many trichomonads (isolate MRP-MT-1). She was given two successive courses of treatment with oral metronidazole (Flagyl, Specia) in a dosage of 500 mg twice daily for five days. Similar treatment was given to her husband. After completion of the treatment the symptoms disappeared and no trichomonads were found in a wet mount preparation. T vaginalis was cultured), however, from vaginal material (isolate MRP-MT-3). Within a month the symptoms had returned and numerous trichomonads were detected in the vaginal exudate.
To determine whether the treatment failure was due to poor absorption of metronidazole the patient was admitted to hospital and given metronidazole in a single oral dose of 2 g. The serum concentrations of the drug were determined two, four, and 24 hours after treatment. Satisfactory concentrations of metronidazole were present in the serum ( Cultures used in the experiments were derived from frozen stabilates and grown in TYM medium without antibiotics. Except for the "Fall River" strain, none of the strains was maintained in active culture at 37°C for longer than three weeks.
SUSCEPTIBILITY ASSAYS
Susceptibility of trichomonads to metronidazole in vitro was estimated as a minimal lethal concentration (MLC) of the drug using an aerobic tube assay. Suspensions of trichomonads (1 x 105 cells/ml) in 1 ml of the aerobic medium (TYM without cysteine and ascorbic acid) were exposed for 48 hours to twofold serial dilutions of metronidazole, and the viability of the parasites was assayed by subsequent cultivation in a drug-free medium. The assay was performed in 100 x 15 mm centrifuge tubes, each containing 0 9 ml of a suspension of parasites in the aerobic TYM and 0 1 ml of the metronidazole solution. The tubes were closed with metal caps allowing equilibration with air. After incubation at 37°C for 48 hours the cells were centrifuged (1600 x g), washed in saline, and resuspended in 5 ml of standard TYM. The metal caps were replaced by non-toxic rubber stoppers and the tubes incubated at 370C for seven days. The MLC at 48 hours (MLC48h) was defined as the lowest concentration of metronidazole at which no viable trichomonads could be detected by cultivation. The assays were run in duplicate and repeated at least twice; additional dilutions were included to refine endpoints.
The in-vitro susceptibility to metronidazole was assayed also under anaerobic conditions in 13 x 100 mm screw-cap tubes (Bellco). Each tube contained 4-4 ml of standard TYM (with reducing co,mpounds included), 0 1 ml of metronidazole solution, and 0 5 ml of trichomonad suspension (to make a final concentration of 1 x ios cells/ml). After 48 hours exposure to metronidazole the cells were washed with saline and resuspended in a drug-free medium.
The in-vivo susceptibility to metronidazole was assayed by estimating the DC50 (dose needed to cure 50% of infections) using the subcutaneous mouse assay described by Meingassner and Thurner.8 Mice were inoculated subcutaneously in each flank with trichomonads which were in the logarithmic phase of growth. Metronidazole was given orally at two, 18, and 24 hours after inoculation. The therapeutic effect was evaluated on day 6 by determining whether viable parasites were present or absent at the site of inoculation (by microscopy and culture). Male albino SPF mice (18) (19) (20) When the efficacy of metronidazole against infection with the isolate MRP-MT-3 was further assayed in vivo in subcutaneously and intraperitoneally infected mice the susceptibility of this isolate to metronidazole was low (table III) . Its relative drug resistance was more pronounced in mice which had been inoculated subcutaneously. The DC50 value of the MRP-MT-3 isolate, calculated from the subcutaneous assays performed in Prague, was about 20 times higher than that of the drugsusceptible control TV 14-85. The highest dose given (3 x 800 mg/kg) was insufficient to obtain a 1000o cure. In Meingassner's experiments none of the mice infected subcutaneously was cured with the highest dose assayed (3 x 400 mg/kg). Intraperitoneal infections with the MRP-MT-3 isolate were successfully cured with metronidazole. The doses necessary for eliminating the infection, however, were relatively high (3 x 400 mg/kg) and the DC50 values about eight times higher than that for the Viennese control strain E (table III) .
The MLC values for six isolates of the MRP-MT strain (table II) showed that throughout the two years of study the protozoon did not respond to repeated treatment by an increase in resistance. 26 and Bacteroides fragi/is27 but not in the drug-tolerant T vagina/is.24 28 29 Metronidazole resistance of the strain of T vaginalis MRP-MT which was reisolated repeatedly from the vagina of our patient did not increase as a result of three unsuccessful courses of treatment; each of the courses apparently exerted considerable selection pressure on the trichomonads. Similarly, increase in resistance was not observed in a strain of T vaginalis isolated in Sweden after treatment with tinidazole.9 In both cases, however, the patients had been treated with nitroimidazoles before initial isolation of the parasite. It is uncertain whether the resistance was induced by inadequate treatment or was intrinsic to the infecting organism.
Recent evidence indicates that metronidazoleresistant strains of T vaginalis cannot be regarded as unique in their incidence. Isolation of resistant strains from patients have been reported in Austria,8 Sweden,9 Britain,'9 20 and the USA.'0 17 18 This calls for a systematic follow-up of treatment failures and extensive surveys of a random population to establish the prevalence of resistant strains. Until then it would be premature to draw conclusions on the clinical importance of metronidazole resistance in strains of T vaginalis. In view of the absence of clinically available drugs which could replace 5-nitroimidazoles, however, the resistance of T vaginalis to metronidazole should be followed with concern.
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